AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

COCHLEAR LTD

135.480

-1.340-0.98%

Volume:485.47K

Turnover:65.88M

Market Cap:8.86B

PE:60.27

High:139.850

Open:135.710

Low:133.930

Close:136.820

52wk High:297.922

52wk Low:88.740

Shares:65.40M

Float Shares:65.14M

Volume Ratio:0.83

T/O Rate:0.75%

Dividend:4.30

Dividend Rate:3.17%

EPS(TTM):2.248

EPS(LYR):2.248

ROE:7.98%

ROA:9.71%

PB:5.09

PE(LYR):60.27

Loading ...

Overview Company News Filings

Near-Term Headwinds Cloud Cochlear's Long-Term Opportunity -- Market Talk

How Do China Reimbursement Cuts Recast Cochlear’s (ASX:COH) Long-Term Margin Story?

Simply Wall St.

Cochlear (ASX:COH) Valuation Check As Earnings Guidance Downgrade Resets Market Expectations

Simply Wall St.

BUZZ-Morningstar backs Australia's Cochlear on new hearing implant product

How Innovation Amid Earnings Pressures At Cochlear (ASX:COH) Has Changed Its Investment Story

Simply Wall St.

Australia R&D Changes Look Positive for CSL, Others -- Market Talk

Australian Dollar Reaches Four-Year Peak: Which ASX Stocks Stand to Gain?

Assessing Cochlear’s Valuation After Its FY26 Earnings Guidance Downgrade

Simply Wall St.

Market Chatter: CSL, Resmed, Cochlear Lead Losses on ASX

MT Newswires Live

How Cochlear’s FY26 Profit Downgrade At Cochlear (ASX:COH) Has Changed Its Investment Story

Simply Wall St.

Cochlear Needs to Keep Promoting Implants as Volume Delays Not Structural, Says Jefferies, Shares Up 4%

MT Newswires Live

Cochlear Bull Thinks Volume Pressures Are Cyclical -- Market Talk

ASX Biggest Losers

MT Newswires Live

Cochlear (ASX:COH) Valuation Check After Guidance Cut And Global Demand Challenges

Simply Wall St.

Cochlear (ASX:COH) Is Down 44.0% After Cutting Profit Outlook Amid Softer Demand And Cost Reset

Simply Wall St.

BUZZ-Australia's Cochlear set for worst week ever on earnings forecast cut

Jarden Adjusts Cochlear's Price Target to AU$169 from AU$224, Keeps at Neutral

MT Newswires Live

Stock Track | Cochlear Plummets 5.02% Intraday Following Analyst Downgrades and Earnings Forecast Cut

Jarden Analysts See Some Hope for Cochlear -- Market Talk

Cochlear Has Limited Scope for Sales Recovery -- Market Talk

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/COH.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"COH.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"COH.AU\",,,,,undefined,":{"symbol":"COH.AU","market":"AU","secType":"STK","nameCN":"COCHLEAR LTD","latestPrice":135.48,"timestamp":1787292720000,"preClose":136.82,"halted":0,"volume":485471,"delay":0,"changeRate":-0.00979388978219561,"nameEN":"COCHLEAR LTD","floatShares":65138365,"shares":65398462,"eps":2.248,"marketStatus":"Not Yet Opened","change":-1.34,"latestTime":"08-21 16:12:00 AEST","open":135.71,"high":139.85,"low":133.93,"amount":65878725,"amplitude":0.043269,"askPrice":135.78,"askSize":228,"bidPrice":134,"bidSize":755,"shortable":3,"etf":0,"ttmEps":2.248,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":136.82,"dividendRate":0.03171,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.8284341027063477,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"COH.AU","preClose":136.82,"auctionPrice":135.56,"auctionVolume":118001,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292600826}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"COH.AU\",,,,,undefined,":{"symbol":"COH.AU","floatShares":65138365,"roa":"9.71%","roe":"7.98%","lyrEps":2.248,"volumeRatio":0.8284341027063477,"shares":65398462,"dividePrice":4.2961,"high":139.85,"amplitude":0.043269,"preClose":136.82,"low":133.93,"week52Low":88.74,"pbRate":"5.09","psRate":"3.77","week52High":297.922,"institutionHeld":0,"latestPrice":135.48,"committee":0.536114,"eps":2.248,"divideRate":0.03171,"volume":485471,"delay":0,"ttmEps":2.248,"open":135.71,"prevYearClose":257.41,"prevWeekClose":133.6,"prevMonthClose":119.94,"prevQuarterClose":121.75,"fiveDayClose":133.6,"twentyDayClose":111.61,"sixtyDayClose":97.4,"dividendPayoutRate":1.9096682506550604,"dividendGrowthYears":5,"dividendGrowthRate":0.0117647058823529,"fiveYearAvgDividendRate":0.018048554743331537},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/COH.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"COH.AU","amount":1.3,"announcedDate":"2026-08-18","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-22","defaultRemindTime":1789948800000,"name":"COCHLEAR LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-14","payableDate":"2026-09-22","currency":"AUD","dateTimestamp":1789912800000,"payDate":"2026-10-14"},{"date":"2026-08-18","symbol":"COH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-19","symbol":"COH.AU","amount":2.15,"announcedDate":"2026-02-12","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-20","name":"COCHLEAR LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-13","payableDate":"2026-03-20","currency":"AUD","dateTimestamp":1773838800000,"payDate":"2026-04-13"},{"date":"2026-02-13","symbol":"COH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770937200000,"name":null,"time":"","dateTimestamp":1770901200000,"actualEps":null},{"date":"2025-09-18","symbol":"COH.AU","amount":2.15,"announcedDate":"2025-08-15","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-19","defaultRemindTime":1758153600000,"name":"COCHLEAR LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-13","payableDate":"2025-09-19","currency":"AUD","dateTimestamp":1758117600000,"payDate":"2025-10-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"COH.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2021-03-25","recordDate":"2021-03-26","paymentDate":"2021-04-20","value":1.15,"currency":"AUD"},{"executeDate":"2021-09-23","recordDate":"2021-09-24","paymentDate":"2021-10-18","value":1.4,"currency":"AUD"},{"executeDate":"2022-03-28","recordDate":"2022-03-29","paymentDate":"2022-04-21","value":1.55,"currency":"AUD"},{"executeDate":"2022-09-21","recordDate":"2022-09-23","paymentDate":"2022-10-17","value":0.87,"currency":"AUD"},{"executeDate":"2023-03-21","recordDate":"2023-03-22","paymentDate":"2023-04-14","value":1.0075,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"COH.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643240662","title":"Near-Term Headwinds Cloud Cochlear's Long-Term Opportunity -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2643240662","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643240662?lang=en_us&edition=fundamental","pubTime":"2026-06-15 12:51","pubTimestamp":1781499060,"startTime":"0","endTime":"0","summary":"0451 GMT - The near-term headwinds facing Cochlear are likely to keep overshadowing the hearing-technology maker's longer-term opportunity, UBS analysts warn. They tell clients in a note that the Middle East conflict remains the key swing factor given the risks around order delays and sovereign collections. The analysts say this has already meant that the Australian company's net profit guidance range is wide for how late in the fiscal year it is. They expect management to give a wide guidance range for the next fiscal year, which would allow room at the bottom end for already challenging conditions to worsen. UBS keeps a neutral rating on the stock and cuts its target price 2.8% to 106.00 Australian dollars. Shares are flat at A$103.75. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COH.AU","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642928907","title":"How Do China Reimbursement Cuts Recast Cochlear’s (ASX:COH) Long-Term Margin Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2642928907","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642928907?lang=en_us&edition=fundamental","pubTime":"2026-06-11 16:34","pubTimestamp":1781166898,"startTime":"0","endTime":"0","summary":"Earlier in June 2026, Cochlear lowered its earnings guidance, citing hospital capacity constraints, geopolitical tensions, and reimbursement cuts in China as key headwinds. \nThis revision has sharpened investor focus on how quickly procedure volumes and profit margins can stabilise in the implantable hearing market. \nWe’ll now explore how Cochlear’s guidance downgrade, particularly the impact of China reimbursement cuts, affects the company’s broader investment narrative. \nFind 10 companies...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/how-do-china-reimbursement-cuts-recast-cochlears-asxcoh-long","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/how-do-china-reimbursement-cuts-recast-cochlears-asxcoh-long","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7007","COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642444531","title":"Cochlear (ASX:COH) Valuation Check As Earnings Guidance Downgrade Resets Market Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2642444531","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642444531?lang=en_us&edition=fundamental","pubTime":"2026-06-10 15:21","pubTimestamp":1781076113,"startTime":"0","endTime":"0","summary":"Why Cochlear’s guidance downgrade matters for investors\nCochlear (ASX:COH) has cut its earnings guidance, citing hospital capacity constraints, geopolitical tensions, and reimbursement changes in China. Following the announcement, the stock fell to an 11 year low, sharpening investor focus on recovery prospects.\nSee our latest analysis for Cochlear.\nThe guidance downgrade comes after a sharp reset in sentiment, with the stock down 60.68% on a year to date share price basis and the 1 year...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-valuation-check-as-earnings-guidance-downgra","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-valuation-check-as-earnings-guidance-downgra","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640192929","title":"BUZZ-Morningstar backs Australia's Cochlear on new hearing implant product","url":"https://stock-news.laohu8.com/highlight/detail?id=2640192929","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640192929?lang=en_us&edition=fundamental","pubTime":"2026-06-03 06:18","pubTimestamp":1780438722,"startTime":"0","endTime":"0","summary":"BUZZ-Morningstar backs Australia's Cochlear on new hearing implant product** Morningstar reiterates A$110 fair value estimate for Cochlear Ltd COH.AX; says shares are slightly undervalued, is more optimistic than the market on resilience of cochlear implant demand** Investment research firm says hearing implant maker will benefit from its new product, Nexa** Says co to realise this from 2H26 as hospital approval bottlenecks resolve and availability improves** Morningstar notes firm earns large proportion of its revenue from sound processor upgrades and accessories used in implants which offsets risk of increased price pressure from competitors** Expects 7% average revenue growth from FY27 vs guidance of about 4% in 2H26, driven by Nexa uptake and penetration in emerging markets with faster birthrates and rising affordability** YTD, COH down 62.9%, as of stock's last close  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nL6N42A18L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4598","MORN","LU2065731478.USD","BK7007","BK4112","LU1878469433.USD","COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640999426","title":"How Innovation Amid Earnings Pressures At Cochlear (ASX:COH) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2640999426","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640999426?lang=en_us&edition=fundamental","pubTime":"2026-06-02 07:26","pubTimestamp":1780356406,"startTime":"0","endTime":"0","summary":"In recent months, Cochlear reported a significant earnings downgrade that weighed on operations amid hospital capacity constraints and foreign exchange headwinds, while also promoting MRI-compatible implant advances during Better Hearing and Speech Month. \nAn interesting angle is how Cochlear’s focus on MRI accessibility and patient wellbeing sits alongside operational pressures, highlighting the balance between innovation investment and near-term business challenges. \nWe’ll now explore how...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/how-innovation-amid-earnings-pressures-at-cochlear-asxcoh-ha","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/how-innovation-amid-earnings-pressures-at-cochlear-asxcoh-ha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635229966","title":"Australia R&D Changes Look Positive for CSL, Others -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2635229966","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635229966?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:27","pubTimestamp":1778628420,"startTime":"0","endTime":"0","summary":"Australian government changes to R&D taxation look positive for locally listed medical manufacturers, RBC Capital Markets analyst Craig Wong-Pan says. The government is increasing the amount of R&D expenditure that companies can claim as a tax offset, while also lifting R&D disbursements paid out from the sovereign Medical Research Future Fund. Wong-Pan thinks this looks like good news for pharmaceutical manufacturer CSL, breath-tech maker ResMed, hearing-implant developer Cochlear and infection-prevention company Nanosonics. From July 2028, the tax offset for experimental core R&D will rise to 50%. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COH.AU","IE00B5TLWC47.USD","BK7067","BK7511","CSL.AU","BK4548","LU2008162690.USD","BK7501","BK4504","SGXZ23171101.USD","BK4567","LU0170899867.USD","RMD","BK7503","BK7508","LU2177674079.SGD","SG9999004303.SGD","LU0728928796.USD","LU1169589451.USD","RMD.AU","BK4086","BK7007","CSL","BK7126","LU1169590202.USD","BK4082","BK4585","BK4588","NAN.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131057162","title":"Australian Dollar Reaches Four-Year Peak: Which ASX Stocks Stand to Gain?","url":"https://stock-news.laohu8.com/highlight/detail?id=1131057162","media":"Trading Random","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131057162?lang=en_us&edition=fundamental","pubTime":"2026-05-07 09:51","pubTimestamp":1778118672,"startTime":"0","endTime":"0","summary":"Amidst the constant stream of significant global developments, it can be challenging to monitor shifts within the Australian financial sector. Observant investors, however, will have noticed a major...","market":null,"thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310799852.SGD","LU0823411888.USD","LU1267930227.SGD","WDS.AU","LU0211328371.USD","BK4597","BK4533","BK4114","BK4017","LU2237443549.SGD","LU2237443382.USD","BK4138","LU1267930490.SGD","BK4076","LU2237443978.SGD","WES.AU","LU1244550221.USD","BK4596","LU1244550577.SGD","LU0310800965.SGD","LU0128525689.USD","COH.AU","BK4532","BK4585","BK4213","BK7142","CSL.AU","BK4156","BK4588","BK4504","JBH.AU","LU1244550494.USD","LU2237443622.USD","WHC.AU","BK4220","LU0052756011.USD","BHP.AU","BK4155","LU0211327993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632279932","title":"Assessing Cochlear’s Valuation After Its FY26 Earnings Guidance Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2632279932","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632279932?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:16","pubTimestamp":1777889791,"startTime":"0","endTime":"0","summary":"Cochlear (ASX:COH) has been in focus after a significant downgrade to its FY26 earnings guidance, with management pointing to softer demand, delayed surgeries, and Middle East disruptions as key pressures on near term performance.\nSee our latest analysis for Cochlear.\nThe share price shock from the April guidance downgrade still dominates the picture, with a 30 day share price return of 41.83% and a year to date share price return of 61.59%. The 1 year total shareholder return of 62.03% and 5...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/assessing-cochlears-valuation-after-its-fy26-earnings-guidan","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/assessing-cochlears-valuation-after-its-fy26-earnings-guidan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632987285","title":"Market Chatter: CSL, Resmed, Cochlear Lead Losses on ASX","url":"https://stock-news.laohu8.com/highlight/detail?id=2632987285","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632987285?lang=en_us&edition=fundamental","pubTime":"2026-05-04 11:54","pubTimestamp":1777866873,"startTime":"0","endTime":"0","summary":"CSL  led losses on the Australian bourse so far this year at AU$23.2 billion, while ResMed  and Cochlear  followed with losses of AU$10.6 billion, the Australian Financial Review reported Monday, citing Global X ETFs.Negative performing companies on the S&P/ASX 200 index collectively wiped out over AU$217 billion, said Marc Jocum, senior product and investment strategist at Global X ETFs.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1169589451.USD","BK7067","XJO.AU","CSL","SGXZ23171101.USD","RMD.AU","BK7007","CSL.AU","LU0728928796.USD","BK4086","COH.AU","BK7508","LU1169590202.USD","BK7511","BK7501","SG9999004303.SGD","DBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623295","title":"How Cochlear’s FY26 Profit Downgrade At Cochlear (ASX:COH) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623295","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632623295?lang=en_us&edition=fundamental","pubTime":"2026-05-02 03:48","pubTimestamp":1777664927,"startTime":"0","endTime":"0","summary":"Cochlear Limited recently downgraded its FY26 net profit guidance from A$435–A$460 million to A$290–A$330 million, citing softer demand, delayed surgeries, and geopolitical disruptions in key markets.\nThis setback has drawn attention to how dependent Cochlear’s earnings are on procedure volumes and hospital capacity, despite its strong competitive position in implantable hearing solutions.\nWe’ll now examine how this earnings guidance cut, driven by weaker demand and delayed surgeries, may...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/how-cochlears-fy26-profit-downgrade-at-cochlear-asxcoh-has-c","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/how-cochlears-fy26-profit-downgrade-at-cochlear-asxcoh-has-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631714502","title":"Cochlear Needs to Keep Promoting Implants as Volume Delays Not Structural, Says Jefferies, Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631714502","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631714502?lang=en_us&edition=fundamental","pubTime":"2026-04-30 14:42","pubTimestamp":1777531352,"startTime":"0","endTime":"0","summary":"Cochlear's  current volume delays are not structural as its volume opportunity for implants remains strong, Jefferies said in a Wednesday note.Jefferies said that US Medicare Advantage and commercial insurance providers require prior authorization for cochlear implantation procedures, which is causing delays in cochlear implant procedure volumes.Cochlear needs to continue promoting the benefits of cochlear implants while also expanding its advocacy programs to support patient access and awareness, the investment firm added.Jefferies kept a buy rating on Cochlear with a price target of AU$137.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631569798","title":"Cochlear Bull Thinks Volume Pressures Are Cyclical -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2631569798","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631569798?lang=en_us&edition=fundamental","pubTime":"2026-04-29 14:59","pubTimestamp":1777445940,"startTime":"0","endTime":"0","summary":"0659 GMT - Cochlear's bull at Jefferies doesn't think the volume pressures experienced by the hearing-implant maker are structural. Maintaining a buy rating on the stock, analyst David Stanton tells clients in a note that rising U.S. Medicare costs and authorization procedures from commercial insurers are delaying volume demand for the Australia-listed company. Most Americans with private insurers are on high-deductable plans, while the growing view among patients and insurers is that cochlear implant procedures are semielective, he adds. However, he says the market remains underpenetrated and Cochlear's volume opportunity is large. Soft demand might be extended but it is merely cyclical, he believes. Jefferies has a A$137.00 target price on the stock, which closed 3.2% lower at A$90.00. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COH.AU","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630652359","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2630652359","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630652359?lang=en_us&edition=fundamental","pubTime":"2026-04-27 11:59","pubTimestamp":1777262349,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech : -3%, AU$42.79NexGen Energy : -3%, AU$17.26Telix Pharmaceuticals : -2%, AU$14.47Cochlear : -2%, AU$94.76Paladin Energy : -2%, AU$12.28Origin Energy : -2%, AU$12.44EVT : -2%, AU$12.44Tuas : -2%, AU$5.97Ramsay Health Care : -2%, AU$39.15Southern Cross Gold : -2%, AU$11.07","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7007","COH.AU","BK7042","BK7130","BK7006","BK7104","BK7016","ORG.AU","EVT.AU","BK7083","BK7503","BK7035","BK7509","SX2.AU","NXG.AU","PDN.AU","BK7113","WTC.AU","TUA.AU","RHC.AU","TLX.AU","BK7507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630740978","title":"Cochlear (ASX:COH) Valuation Check After Guidance Cut And Global Demand Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2630740978","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630740978?lang=en_us&edition=fundamental","pubTime":"2026-04-25 10:12","pubTimestamp":1777083176,"startTime":"0","endTime":"0","summary":"Cochlear (ASX:COH) is back in focus after the company cut its fiscal year profit guidance, citing softer demand in the US, surgical capacity constraints in Western Europe, and external risks in China and the Middle East.\nSee our latest analysis for Cochlear.\nThe steep guidance cut has been met with a sharp reset in sentiment, with a 7 day share price return of 42.21% decline and a 1 year total shareholder return of 62.47% decline pointing to fading momentum, even as management reiterates its...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-valuation-check-after-guidance-cut-and-globa","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-valuation-check-after-guidance-cut-and-globa","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["COH.AU","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629489319","title":"Cochlear (ASX:COH) Is Down 44.0% After Cutting Profit Outlook Amid Softer Demand And Cost Reset","url":"https://stock-news.laohu8.com/highlight/detail?id=2629489319","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629489319?lang=en_us&edition=fundamental","pubTime":"2026-04-24 09:08","pubTimestamp":1776992934,"startTime":"0","endTime":"0","summary":"Cochlear Limited recently cut its fiscal-year profit outlook after softer-than-expected demand, citing weaker US consumer sentiment, surgical capacity constraints in Western Europe, and external headwinds including geopolitical tensions and reduced reimbursement in China.\nWhile management reiterated confidence in its long-term growth strategy, it also flagged the need to reshape its cost base to better align with current demand conditions and external risks.\nWe’ll now examine how the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-is-down-440-after-cutting-profit-outlook-ami","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-is-down-440-after-cutting-profit-outlook-ami","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4587","BK4585","ARTY","BK7007","CHAT","AIYY","BK4543","COH.AU","AI","BK4551","BK4023","BK4588","AIPO","AGIX","BK4528"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629886708","title":"BUZZ-Australia's Cochlear set for worst week ever on earnings forecast cut","url":"https://stock-news.laohu8.com/highlight/detail?id=2629886708","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629886708?lang=en_us&edition=fundamental","pubTime":"2026-04-24 08:51","pubTimestamp":1776991888,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Cochlear set for worst week ever on earnings forecast cut** Shares of Cochlear COH.AX on track for worst week ever, down 42.7%** Stock's relative strength index remains below 30, a level widely seen as signalling oversold conditions** COH stock crashed over 40% on Wednesday after co slashed its forecast for annual earnings** Citi downgraded rating to \"sell\", reduced price target to A$95/shr on Thursday** \"This guidance downgrade is far worse than anticipated\" - Jarden on Wednesday** Stock down 62.8% YTD, including the day's moves  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nL4N41703K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COH.AU","CNS","BK4135","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629841608","title":"Jarden Adjusts Cochlear's Price Target to AU$169 from AU$224, Keeps at Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2629841608","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629841608?lang=en_us&edition=fundamental","pubTime":"2026-04-23 17:41","pubTimestamp":1776937271,"startTime":"0","endTime":"0","summary":"Cochlear (ASX:COH) has an average rating of overweight and mean price target of AU$166.45, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169620205","title":"Stock Track | Cochlear Plummets 5.02% Intraday Following Analyst Downgrades and Earnings Forecast Cut","url":"https://stock-news.laohu8.com/highlight/detail?id=1169620205","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169620205?lang=en_us&edition=fundamental","pubTime":"2026-04-23 11:22","pubTimestamp":1776914566,"startTime":"0","endTime":"0","summary":"Cochlear Ltd's stock fell 5.02% during intraday trading on Thursday, extending recent heavy losses for the hearing implant maker.The decline follows a series of analyst rating downgrades and a...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629355070","title":"Jarden Analysts See Some Hope for Cochlear -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2629355070","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629355070?lang=en_us&edition=fundamental","pubTime":"2026-04-23 09:34","pubTimestamp":1776908040,"startTime":"0","endTime":"0","summary":"0134 GMT - Cochlear won't get a good start to its next fiscal year but there is still some cause for optimism, Jarden analysts say. While the hearing implant maker has slashed its FY 2026 profit guidance on weak unit sales, the Jarden analysts tell clients in a note that the Australian company's services segment appears to be rebounding into fiscal 2027. Elsewhere, they acknowledge that competition is making acoustics revenue growth unpredictable, but still cite 11% March-quarter growth as a positive. Jarden cuts its target price on the stock 25% to A$169.00 and maintains a neutral rating. Shares are down 1.4% at A$98.19. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","COH.AU","BK7007","HOPE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629778620","title":"Cochlear Has Limited Scope for Sales Recovery -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2629778620","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629778620?lang=en_us&edition=fundamental","pubTime":"2026-04-23 09:04","pubTimestamp":1776906240,"startTime":"0","endTime":"0","summary":"0104 GMT - Cochlear loses its buy rating at UBS, where analysts see limited scope for the hearing-implant maker to lift annual sales growth back to 10% any time soon. Cutting their recommendation to neutral, the investment bank's analysts tell clients that a drop in U.S. unit sales at a time when Cochlear is releasing a new implant into a vast underpenetrated adult market is a clear negative. They say that overburdened European health systems and reimbursement cuts in China add to the pressure on sales. The analysts warn that the challenges facing the Australian company are entrenched, with earnings visibility at a post-Covid low. UBS slashes its target price 64% to A$109.00. Shares are down 2.2% at A$97.40. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","COH.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":106,"code":"91000000","status":"200"}]}}